 |
PDBsum entry 2c30
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transferase
|
 |
|
Title:
|
 |
Crystal structure of the human p21-activated kinase 6
|
|
Structure:
|
 |
Serine/threonine-protein kinase pak 6. Chain: a. Fragment: kinase domain, residues 383-681. Synonym: p21-activated kinase 6, pak-6, pak-5. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562
|
|
Resolution:
|
 |
|
1.60Å
|
R-factor:
|
0.198
|
R-free:
|
0.222
|
|
|
Authors:
|
 |
P.Filippakopoulos,G.Berridge,J.Bray,N.Burgess,S.Colebrook,S.Das, J.Eswaran,O.Gileadi,E.Papagrigoriou,P.Savitsky,C.Smee,A.Turnbull, M.Sundstrom,C.Arrowsmith,J.Weigelt,A.Edwards,F.Von Delft,S.Knapp
|
Key ref:
|
 |
J.Eswaran
et al.
(2007).
Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs.
Structure,
15,
201-213.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
02-Oct-05
|
Release date:
|
08-Feb-06
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
Q9NQU5
(PAK6_HUMAN) -
Serine/threonine-protein kinase PAK 6 from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
681 a.a.
290 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.11.1
- non-specific serine/threonine protein kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Structure
15:201-213
(2007)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal Structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs.
|
|
J.Eswaran,
W.H.Lee,
J.E.Debreczeni,
P.Filippakopoulos,
A.Turnbull,
O.Fedorov,
S.W.Deacon,
J.R.Peterson,
S.Knapp.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
p21-activated kinases have been classified into two groups based on their domain
architecture. Group II PAKs (PAK4-6) regulate a wide variety of cellular
functions, and PAK deregulation has been linked to tumor development. Structural
comparison of five high-resolution structures comprising all active,
monophosphorylated group II catalytic domains revealed a surprising degree of
domain plasticity, including a number of catalytically productive and
nonproductive conformers. Rearrangements of helix alphaC, a key regulatory
element of kinase function, resulted in an additional helical turn at the alphaC
N terminus and a distortion of its C terminus, a movement hitherto unseen in
protein kinases. The observed structural changes led to the formation of
interactions between conserved residues that structurally link the glycine-rich
loop, alphaC, and the activation segment and firmly anchor alphaC in an active
conformation. Inhibitor screening identified six potent PAK inhibitors from
which a tri-substituted purine inhibitor was cocrystallized with PAK4 and PAK5.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Figure 3. Binding of the Purine Inhibitor (A and B)
Superimposition of PAK4 and PAK5 showing the (A) binding modes
of the purine inhibitor and (B) interaction with active site
residues in PAK4. A superimposition of the C-terminal lobes was
used to generate the figure shown in (A). PAK4 is shown in
yellow, and PAK5 is shown in orange.
|
 |
Figure 5.
Figure 5. Rearrangement of Helix αC (A) Superimposition
of central residues in the PAK5 αC helices showing the
remodeling of the αC termini. The central residues stay in
position, whereas conversion into an active state (PAK5 purine
complex) results in the addition of an N-terminal α helix and
disruption of the αC terminus. (B) Structural changes at
the αC C terminus brings Asn493 (Asn365, PAK4) into position to
hydrogen bond with the DFG glycine (Gly588) and a conserved
activation segment cysteine (Cys590 and Cys462 in PAK5 and PAK4,
respectively), resulting in the formation of the αC anchor
point with the activation segment. In the PAK4 structures, this
movement is not completed, and only one hydrogen bond is formed
with Cys462. (C) Swinging movement of the conserved αC
Arg487 (Arg359 in PAK4) between the glycine-rich loop and the
phosphoserine activation loop residue. Upon extension of the αC
helix by one turn at the N –terminus, Arg487 forms three
hydrogen bonds with the glycine-rich loop, stabilizing an
extremely closed conformation (PAK5 purine complex, orange). In
the short αC conformation, the corresponding arginine in PAK4
interacts with the phosphoserine residue in the activation
segment. This conformation also results in a partially open
conformation of the glycine-rich loop stabilized by a hydrogen
bond formed by the conserved Gln357. When αC swings away (as
observed in apo-PAK5, cyan, or PAK6 [not shown]), the N- and
C-terminal anchor points break, resulting in an open
glycine-rich loop conformation. During the swinging movement,
Arg487 in the PAK5 apo structure was observed in a disordered
state beyond the γ carbon (indicated by white balls and
sticks).
|
 |
|
|
|
| |
The above figures are
reprinted
from an Open Access publication published by Cell Press:
Structure
(2007,
15,
201-213)
copyright 2007.
|
|
| |
Figures were
selected
by the author.
|
|
|
| |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
|
| |
p21 activated kinases have been classified into two groups based on their domain architecture. Group II PAKs (PAK4-6) regulate a wide variety of cellular functions and PAK deregulation has been linked to tumor development. Here, we report a new mechanism of kinase activation revealed by comparison of five high-resolution structures comprising all group II family members. Structural comparison revealed a rearrangement of helix alpha-C, a key regulatory element of kinase function resulting in an additional helical turn at the alpha-C N-terminus and a distortion the alpha-C C-terminus, a movement hitherto unseen in protein kinases. The observed structural changes led to the formation of interactions between conserved residues which structurally link the glycine rich loop, alpha-C and the activation segment and firmly anchor alpha-C in an active conformation.
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
B.W.Murray,
C.Guo,
J.Piraino,
J.K.Westwick,
C.Zhang,
J.Lamerdin,
E.Dagostino,
D.Knighton,
C.M.Loi,
M.Zager,
E.Kraynov,
I.Popoff,
J.G.Christensen,
R.Martinez,
S.E.Kephart,
J.Marakovits,
S.Karlicek,
S.Bergqvist,
and
T.Smeal
(2010).
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.
|
| |
Proc Natl Acad Sci U S A,
107,
9446-9451.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.M.Wells,
and
G.E.Jones
(2010).
The emerging importance of group II PAKs.
|
| |
Biochem J,
425,
465-473.
|
 |
|
|
|
|
 |
J.Eswaran,
and
S.Knapp
(2010).
Insights into protein kinase regulation and inhibition by large scale structural comparison.
|
| |
Biochim Biophys Acta,
1804,
429-432.
|
 |
|
|
|
|
 |
T.P.Ko,
W.Y.Jeng,
C.I.Liu,
M.D.Lai,
C.L.Wu,
W.J.Chang,
H.L.Shr,
T.J.Lu,
and
A.H.Wang
(2010).
Structures of human MST3 kinase in complex with adenine, ADP and Mn2+.
|
| |
Acta Crystallogr D Biol Crystallogr,
66,
145-154.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Y.W.Ng,
D.Raghunathan,
P.M.Chan,
Y.Baskaran,
D.J.Smith,
C.H.Lee,
C.Verma,
and
E.Manser
(2010).
Why an A-loop phospho-mimetic fails to activate PAK1: understanding an inaccessible kinase state by molecular dynamics simulations.
|
| |
Structure,
18,
879-890.
|
 |
|
|
|
|
 |
A.Kumar,
P.R.Molli,
S.B.Pakala,
T.M.Bui Nguyen,
S.K.Rayala,
and
R.Kumar
(2009).
PAK thread from amoeba to mammals.
|
| |
J Cell Biochem,
107,
579-585.
|
 |
|
|
|
|
 |
J.Eswaran,
M.Soundararajan,
and
S.Knapp
(2009).
Targeting group II PAKs in cancer and metastasis.
|
| |
Cancer Metastasis Rev,
28,
209-217.
|
 |
|
|
|
|
 |
L.K.McNamara,
D.M.Watterson,
and
J.S.Brunzelle
(2009).
Structural insight into nucleotide recognition by human death-associated protein kinase.
|
| |
Acta Crystallogr D Biol Crystallogr,
65,
241-248.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.Anand,
J.Maksimoska,
N.Pagano,
E.Y.Wong,
P.A.Gimotty,
S.L.Diamond,
E.Meggers,
and
R.Marmorstein
(2009).
Toward the development of a potent and selective organoruthenium mammalian sterile 20 kinase inhibitor.
|
| |
J Med Chem,
52,
1602-1611.
|
 |
|
|
|
|
 |
A.C.Pike,
P.Rellos,
F.H.Niesen,
A.Turnbull,
A.W.Oliver,
S.A.Parker,
B.E.Turk,
L.H.Pearl,
and
S.Knapp
(2008).
Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites.
|
| |
EMBO J,
27,
704-714.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
F.Villa,
M.Deak,
D.R.Alessi,
and
D.M.van Aalten
(2008).
Structure of the OSR1 kinase, a hypertension drug target.
|
| |
Proteins,
73,
1082-1087.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Eswaran,
M.Soundararajan,
R.Kumar,
and
S.Knapp
(2008).
UnPAKing the class differences among p21-activated kinases.
|
| |
Trends Biochem Sci,
33,
394-403.
|
 |
|
|
|
|
 |
J.Weigelt,
L.D.McBroom-Cerajewski,
M.Schapira,
Y.Zhao,
C.H.Arrowsmith,
and
C.H.Arrowmsmith
(2008).
Structural genomics and drug discovery: all in the family.
|
| |
Curr Opin Chem Biol,
12,
32-39.
|
 |
|
|
|
|
 |
K.K.Ojo,
J.R.Gillespie,
A.J.Riechers,
A.J.Napuli,
C.L.Verlinde,
F.S.Buckner,
M.H.Gelb,
M.M.Domostoj,
S.J.Wells,
A.Scheer,
T.N.Wells,
and
W.C.Van Voorhis
(2008).
Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy.
|
| |
Antimicrob Agents Chemother,
52,
3710-3717.
|
 |
|
|
|
|
 |
G.Bunkoczi,
E.Salah,
P.Filippakopoulos,
O.Fedorov,
S.Müller,
F.Sobott,
S.A.Parker,
H.Zhang,
W.Min,
B.E.Turk,
and
S.Knapp
(2007).
Structural and functional characterization of the human protein kinase ASK1.
|
| |
Structure,
15,
1215-1226.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
O.Gileadi,
S.Knapp,
W.H.Lee,
B.D.Marsden,
S.Müller,
F.H.Niesen,
K.L.Kavanagh,
L.J.Ball,
F.von Delft,
D.A.Doyle,
U.C.Oppermann,
and
M.Sundström
(2007).
The scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteins.
|
| |
J Struct Funct Genomics,
8,
107-119.
|
 |
|
|
|
|
 |
U.E.Rennefahrt,
S.W.Deacon,
S.A.Parker,
K.Devarajan,
A.Beeser,
J.Chernoff,
S.Knapp,
B.E.Turk,
and
J.R.Peterson
(2007).
Specificity profiling of Pak kinases allows identification of novel phosphorylation sites.
|
| |
J Biol Chem,
282,
15667-15678.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |